| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AVAH | Common Stock, $0.01 par value | Sale | -$974 | -173 | 0% | $5.63 | 31.4M | Mar 24, 2025 | By J.H. Whitney VII, L.P. | F1, F2, F4 |
| transaction | AVAH | Common Stock, $0.01 par value | Sale | -$654 | -116 | 0% | $5.64 | 31.4M | Mar 25, 2025 | By J.H. Whitney VII, L.P. | F1, F3, F4 |
| transaction | AVAH | Common Stock, $0.01 par value | Sale | -$490 | -87 | 0% | $5.63 | 15.7M | Mar 24, 2025 | By PSA Healthcare Investment Holding LLC | F1, F2, F4 |
| transaction | AVAH | Common Stock, $0.01 par value | Sale | -$327 | -58 | 0% | $5.64 | 15.7M | Mar 25, 2025 | By PSA Healthcare Investment Holding LLC | F1, F3, F4 |
| transaction | AVAH | Common Stock, $0.01 par value | Sale | -$45 | -8 | 0% | $5.63 | 1.45M | Mar 24, 2025 | By PSA Iliad Holdings LLC | F1, F2, F4 |
| transaction | AVAH | Common Stock, $0.01 par value | Sale | -$28 | -5 | 0% | $5.64 | 1.45M | Mar 25, 2025 | By PSA Iliad Holdings LLC | F1, F3, F4 |
| holding | AVAH | Common Stock, $0.01 par value | 0 | Mar 24, 2025 | Direct | F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The reported sale occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by J.H. Whitney VII, L.P. ("JHW VII"), PSA Healthcare Investment Holding LLC ("PSA Healthcare"), JHW Iliad Holdings LLC, PSA Iliad Holdings LLC ("PSA Iliad Holdings," and, collectively with JHW VII and PSA Healthcare, the "Stockholder Entities") and JHW Iliad Holdings II LLC on December 13, 2024. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.62 to $5.63. The reporting persons hereby undertake to provide, upon request, to the staff of the Securities and Exchange Commission ("SEC"), the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.63 to $5.65. The reporting persons hereby undertake to provide, upon request, to the staff of the SEC, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| F4 | J.H. Whitney Equity Partners VII, LLC ("Equity Partners VII") is the general partner of JHW VII and Whitney Strategic Partners VII, L.P. ("Strategic Partners VII"). Strategic Partners VII is the managing member of each of PSA Healthcare, and PSA Iliad Holdings. As a result, Equity Partners VII may be deemed to share voting and dispositive power with respect to the shares held by each of the Stockholder Entities, and Strategic Partners VII may be deemed to share voting and dispositive power with respect to the shares held by each of PSA Healthcare and PSA Iliad Holdings. Each of Equity Partners VII and Strategic Partners VII disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
Exhibit List: Exhibit 24 - Confirming Statement